Myriad Genetics is to expand its partnership with MSD and AstraZeneca to use its BRACAnalysis CDx test to identify men with metastatic, castrate-resistant prostate cancer and germline BRCA mutations who are likely to respond to olaparip. If the study is successful, Myriad will file a supplementary premarket approval application with the FDA for use of BRACAnalysis CDx as a companion diagnostic for the drug for this patient population. BRACAnalysis CDx has already been approved by the FDA as a companion test for olaparip in several ovarian and breast cancer indications.
“Myriad Genetics expands AZ and MSD partnership“
Nicole Lambert, president of Myriad Oncology, said: "There is a significant unmet medical need in men with metastatic, castration-resistant prostate cancer and BRCA1/2 mutations, which is an area where the utility of PARP inhibitors is being explored."